Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes
Higher OOP payment decreased the antiviral prescription rate, potentially leading to clinical and economic loss.
Authors
- Mitsuhiro Nagano
- Tendai Mugwagwa (ORCID: https://orcid.org/0000-0001-7515-8548)
- Kanae Togo (ORCID: https://orcid.org/0000-0003-3964-4009)
- Akira Yuasa (ORCID: https://orcid.org/0000-0002-3699-7231)
- Sachiko Hyokai
Institutions
- Pfizer (United States) (US)
- Pfizer (Japan) (JP)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1080/14737167.2024.2410963
- Citations
- 3
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Pfizer Japan